We explored a possible role for the basic fibroblast growth factor (FGF) receptor during herpes simplex virus type 1 (HSV-1) infection of primary mouse astrocytes, glial cells of the central nervous system known to express FGF receptors. Plaque reduction experiments showed that treatment of astrocyte monolayers with human recombinant basic FGF failed to inhibit HSV-1 infectivity, although treatment with either heparin or poly-L-lysine reduced it by approximately 100%. Identical results were obtained when monolayers of human embryonic lung fibroblasts or African green monkey kidney cells were treated with FGF, heparin or poly-L-lysine prior to HSV-1 infection. We conclude that the basic FGF receptor is not involved in the uptake of HSV-1 during productive infection of astrocytes. Our findings suggest that this molecule is not the predominant cellular receptor for HSV-1 among vertebrate cells and plays no role in defining HSV-1 neurotropism in vivo.
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Viruses exploit cell surface molecules as receptors for binding and entry into cells. In the case of herpes simplex virus type 1 (HSV-1), WuDunn & Spear (1989) initially provided evidence that cell surface heparan sulphate serves as the primary virus receptor during productive infection of HEp-2 cells. Experiments have demonstrated that virions bind to heparin and that heparin blocks virus adsorption. In addition, poly-Lqysine, a polycation known to bind to cell surface heparan sulphate, also blocks virus adsorption and infection. Finally, enzymatic digestion of cell surface heparan sulphate has been found to reduce the binding of virus to cells and thereby renders them resistant to infection. A role for this ubiquitous cell surface molecule during initial virus attachment would help to explain the broad host range of HSV-1 among vertebrate cells in culture.
Recently, Kaner et al. (1990) have reported that treatment of bovine arterial smooth muscle cells with basic fibroblast growth factor (FGF) at a concentration of 100 nM blocks HSV-1 uptake and infectivity by approximately 70% and 90%, respectively. Moreover, Chinese hamster ovary cells, which do not express FGF receptors and are resistant to HSV-1 infection, have been found to support HSV-1 uptake when transfected with DNA encoding a basic FGF receptor. These workers concluded that the receptor for basic FGF serves an additional function as a 'portal of entry' for HSV-1 into the cell. Since cells of the nervous system are rich in basic FGF (Ferrara et al., 1988; Finklestein et ai., 1988;  0001-0882 © 1992 SGM Frautschy et al., 1991 ; Kiyota et al., 1991 ; Pettmann et al., 1986; ToreUi et al., 1986) , this observation would account for the neurotropism of HSV-I in vivo.
We performed experiments to confirm the putative role of the basic FGF receptor during HSV-1 infection and to explore the potential strain specificity of the receptor function. We initially focused our attention on HSV-1 infection of astrocytes, cells of the central nervous system (CNS) known to express basic FGF receptors (Ferrara et al., 1988) . Monolayers of primary astrocytes were prepared from the cerebral cortices of 1-day-old BALB/c mice as described previously (Tedeschi et al., 1986) . After 2 weeks in culture, the purity of the cell population was assessed immunohistochemically using rabbit antibodies against glial fibrillary acidic protein (GFAP), a protein found only in astrocytes. Microglia were identified with 1,1'-dioctadecyl-l,3,3,3',3'-tetramethyl indocarbocyanine perchlorate, which labels an acetylated low density lipoprotein (ac-LDL) specific for mononuclear cells. Oligodendrocyte-specific antigens were identified immunohistochemically using mouse monoclonal antibodies directed against galactocerebroside (GalC) and 04 antigen. Over 99% of the cells were GFAP-positive after 2 weeks in culture. The few contaminating cells (< 1%) proved to be oligodendrocytes (GalC + and 04 +) or microglia (ac-LDL+).
Monolayers were treated for 2 h at 37 °C with 10, 100 or 1000 nM-human recombinant basic FGF (Boehringer Mannheim) or PBS and then inoculated with either Short communication HSV-1 strain F or H299 at a multiplicity that yielded 50 to 250 individual plaques per monolayer. It is noteworthy that the F strain used in these experiments is a high passage laboratory virus employed by Kaner et al. (1990) during their original FGF work, whereas the H299 strain is a low passage clinical isolate of neural origin (Lewis et al., 1989) . Following a 2 h incubation at 37 °C, the monolayers were overlaid with Dulbecco's MEM containing 10% foetal calf serum and 2% methylcellulose, and incubated for an additional 48 to 72 h at 37 °C to allow formation of detectable plaques. When compared with infected monolayers treated with PBS, FGF-treated monolayers at all concentrations tested produced approximately the same number of plaques (Table 1 ). In addition, identical results were obtained with HSV-1 strains F and H299. However, in sharp contrast, treatment of mouse astrocyte monolayers for 2 h at 37 °C with either 100 ~g/ml heparin (Mr 7500) or 10 ~tg/ml poly-L-lysine (both purchased from Sigma), followed by virus inoculation, reduced HSV-1 strain H299 plaque formation by 97% and 100%, respectively (Table 1) . Thus, whereas heparin or poly-L-lysine treatment effectively reduced or eliminated the infectivity of HSV-1 for primary mouse astrocytes, FGF treatment failed to reduce the infectivity of HSV-1 for these neural cells even at a concentration 10-fold that used by Kaner et al. (1990) .
This result using glial cells of the CNS prompted us to explore the effect of FGF treatment on the infectivity of HSV-1 for human embryonic lung (HEL) fibroblasts and African green monkey kidney (Vero) cells, two cell lines commonly used to study HSV-1 replication in the laboratory. Parallel plaque reduction experiments were performed using monolayers of HEL and Vero cells as described above for primary mouse astrocytes. However, in these experiments, purified bovine basic FGF (Boehringer Mannheim) at concentrations of 7-5 and 75 nM was used as well as human recombinant basic FGF at concentrations of 10 and 100 riM. Two additional HSV-1 strains, KOS-63 (a high passage laboratory strain) and KOS-79 (a low passage clinical isolate recovered from a recurrent lip lesion) (Dix et al., 1983) , were also included in these experiments to explore more fully the potential influence of virus strain on experimental outcome. * Cultures were infected with HSV-I strain H299 at a multiplicity of 20 p.f.u./cell as described in the text.
t Cultures were treated with either PBS or 100 nM human recombinant basic FGF for 2 h prior to infection as described in the text.
:~ P.f.u./ml determined by quantitative plaque assay on Vero cells.
Treatment with either bovine FGF or human recombinant FGF at all concentrations tested failed to alter the infectivity of HSV-1 for HEL or Vero cells (Table 2) , although heparin and poly-L-lysine effectively reduced HSV-1 plaque formation in these cell lines. Moreover, virus strain had no apparent effect on experimental outcome; all strains tested, including the F strain, produced equivalent number of plaques in either the presence or absence of FGF treatment (Table 2) . Plaque reduction assays are dependent upon cytopathology as a measure of HSV-1 infection, but do not assess overall virus production. Therefore it is possible that FGF treatment reduces the overall production of infectious virus but allows virus-induced cytopathology to occur. To explore this possibility, monolayers of primary mouse astrocytes were treated with either PBS or 100 nM human recombinant basic FGF for 2 h at 37 °C, incubated for 1 h with HSV-1 strain H299 at an m.o.i, of 20 p.f.u./cell, harvested 24 h post-infection, and subjected to a quantitative plaque assay to determine the extent of production of infectious progeny virus. Results revealed that untreated or FGF-treated, HSV-l-infected mouse astrocyte monolayers produced equivalent amounts of infectious virus 24 h post-infection (Table 3) .
Additional evidence showing that productive infection of mouse astrocytes by HSV-1 strain H299 is unaltered despite pretreatment with basic FGF was provided by analysis of virus-induced polypeptide synthesis. Astrocyte monolayers were incubated for 2 h at 37 °C in either the absence or presence of 100 nM human recombinant basic FGF, infected with HSV-1 strain H299 at a multiplicity of 20 p.f.u./cell, labelled with [3SS]methionine (sp. act. 50 IxCi/ml) 4 h postinfection and harvested 24 h post-infection. SDSpolyacrylamide slab gel analysis demonstrated identical patterns of virus-induced polypeptide synthesis in both untreated and FGF-treated virus-infected astrocytes (data not shown).
In summary, we have been unable to reproduce the findings of Kaner et al. (1990) , who demonstrated that pretreatment of bovine arterial smooth muscle cells with basic FGF reduces HSV-1 strain F uptake by approximately 70~ and its infectivity by approximately 90 ~o. In our hands, basic FGF treatment of cultures of primary mouse astrocytes, HEL cells or Vero cells failed to alter HSV-I infectivity, although heparin or poly-L-lysine treatment effectively reduced HSV-1 infectivity. Both human and bovine FGF failed to block HSV-1 infectivity, indicating that the origin of the basic FGF was not a factor in these studies. Finally, all HSV-1 strains tested, including the F strain, proved to be infectious in the presence of basic FGF. Therefore we conclude that the basic FGF receptor is not required for HSV-1 infection. This conclusion is supported by the recent work of Mirda et al. (1992) who have demonstrated that rat L6 myoblasts lacking FGF receptors are as susceptible to HSV-1 strain F infection as L6 cells genetically engineered to express the FGF receptor.
The difference between our findings and those presented by Kaner et al. (1990) might be attributed to the different cell lines used in the respective studies. Their study used cultures of bovine arterial smooth muscle cells. It is conceivable that these cells are endowed with unique properties that contributed in unexpected ways to the outcome of their experiments, especially because bovine arterial cells have been employed previously in bioassays for FGFs (Gospodarowicz et al., 1976 (Gospodarowicz et al., , 1984 .
Our finding that heparin or poly-L-lysine treatment effectively inhibits HSV-1 infection of mouse astrocytes, HEL cells and Vero cells is in agreement with the work of WuDunn & Spear (1989) . This observation, coupled with our inability to inhibit HSV-1 infection of these cells by basic FGF treatment, would support the conclusion that heparan sulphate is the predominant cellular receptor for HSV-1 on vertebrate cells, including glial cells of the CNS. This conclusion would not dismiss a role for the basic FGF receptor during HSV-1 infection of exceptional cell lines such as bovine arterial smooth muscle cells. However, our findings would argue against a role for the receptor molecule in defining the neurotropism displayed by HSV-1 in vivo because astrocytes remain permissive for HSV-1 infection despite pretreatment with basic FGF. Clearly, additional work must be done to identify the precise receptor molecule(s) which serves to govern HSV-1 neurotropism and ultimately neuronal latency during clinical infection. 
